Cartesian Therapeutics' 15min chart shows KDJ Death Cross, Bearish Marubozu formation.

According to the 15-minute chart for Cartesian Therapeutics, a significant technical indicator, the KDJ Death Cross, has been triggered, accompanied by a bearish Marubozu pattern at 08/11/2025 14:00. This suggests a shift in momentum towards the downside, indicating a potential further decrease in the stock price. The sellers appear to be in control of the market, and this bearish momentum is likely to persist.

Cartesian Therapeutics Inc. (RNAC) reported its second-quarter 2025 financial results on August 7, 2025, revealing a significant drop in GAAP revenue and a net income figure that exceeded expectations [2]. However, a recent technical analysis indicates a potential downturn in the stock price, with the KDJ Death Cross and a bearish Marubozu pattern suggesting a shift in momentum towards the downside [3].

The company reported a GAAP net income of $15.9 million and an earnings per share (EPS) of $0.51, which surpassed estimates by $1.31 [2]. Despite this positive earnings surprise, the GAAP revenue declined by 99.1% from the prior year, dropping to $0.298 million [2]. This sharp decline in revenue was primarily due to the absence of significant collaboration and license payments from the previous year.

The quarter also saw an increase in research and development expenses to $14.9 million, up from $12.7 million in the prior year, reflecting the start of the pivotal Phase 3 AURORA trial for Descartes-08 in myasthenia gravis [2]. The AURORA trial is designed to assess improvement in patient activity of daily living scores and offers a potential path to registration if successful. The company's cash balance stood at $160.3 million as of June 30, 2025, which management expects to fund operations through mid-2027 [2].

Technical indicators, however, suggest a bearish trend. A significant technical indicator, the KDJ Death Cross, was triggered on August 11, 2025, at 14:00, accompanied by a bearish Marubozu pattern [3]. This pattern indicates a shift in momentum towards the downside, suggesting a potential further decrease in the stock price. The sellers appear to be in control of the market, and this bearish momentum is likely to persist.

Investors should closely monitor the AURORA trial enrollment progress, interim data announcements, and the start of additional trials in pediatric autoimmune conditions in the second half of 2025. Positive trial readouts, regulatory timelines, and the ability to transition from milestones to commercial product sales will be crucial for the company's future value.

References:
[1] Cartesian Therapeutics reports second quarter 2025 financial results and provides business update. Retrieved from https://www.marketscreener.com/news/cartesian-therapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update-ce7c5edfdc8afe24
[2] Cartesian RNAC Q2 revenue drops 99%. Retrieved from https://www.nasdaq.com/articles/cartesian-rnac-q2-revenue-drops-99
[3] JesterAI. Cartesian Therapeutics: Technical Analysis. Retrieved from https://www.jesterai.com/cartesian-therapeutics-technical-analysis